Pfizer's new cancer drug combo tested in tiny early trial
NCT ID NCT06974734
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08046037 (also called SGN-PDL1iT) and sasanlimab
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers that have stopped responding to other therapies.
What could go wrong
This was a very early Phase 1 trial with only 8 participants, and it was terminated early. It is too small and preliminary to know if the drug is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Community Health Network, Inc
Indianapolis, Indiana, 46219, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46227, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46250, United States
-
Community Health Network, Inc.
Indianapolis, Indiana, 46256, United States
-
Pan American Center for Oncology Trials, LLC
Rio Piedras, 00935, Puerto Rico
-
Presbyterian/ St. Lukes Medical Center
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut, 06611, United States
-
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut, 06510, United States
-
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut, 06511, United States
-
Tristar Centennial Medical Center
Nashville, Tennessee, 37203, United States
-
Yale - New Haven Hospital - Yale Cancer Center
New Haven, Connecticut, 06510, United States